Jubilant Pharmova Limited — Important, 12-03-2025: General Updates

Jubilant Cadista Pharmaceuticals Inc., a subsidiary of Jubilant Pharmova, has received an Establishment Inspection Report (EIR) from the USFDA, indicating a Voluntary Action Indicated (VAI) status for its solid oral formulations facility in Salisbury, Maryland. The inspection, conducted in January 2025, has now been successfully closed. However, it’s important to note that this facility will not continue manufacturing any products, following the earlier disclosure that noted a closure of its manufacturing operations. This development may impact the operational landscape for Jubilant Pharmova by removing production capabilities, but it also closes off regulatory concerns tied to the facility’s compliance status. Investors should keep a close eye on how this situation unfolds, as it could influence the company's strategic focus in the US market.